GlaxoSmithKline (GSK) fired former US government vaccine chief Dr Moncef Slaoui from his post as chairman of a company controlled by the UK drug maker after an internal investigation found he sexually harassed an employee from GSK several years ago.
GSK clarified that the termination of Dr Moncef Slaoui’s contract with Galvani Bioelectronics was effective immediately. The former chief adviser to the US Covid-19 vaccine development program, known as Operation Warp Speed, was not immediately available for comment by phone.
GSK added that an investigation into the conduct of Dr Moncef Slaoui had corroborated the allegations of harassment and inappropriate contact, noting that the investigation was ongoing. The termination of Dr Moncef Slaoui’s contract follows receipt of a letter containing allegations of improper conduct by the GSK employee, the company said in a statement. The British manufacturer clarified that the allegations dated back to when Moncef Slaoui was an employee of GSK.
Prior to his position at Galvani, Dr Moncef Slaoui spent nearly 30 years at GlaxoSmithKline, holding various management positions, including that of Head of Pharmaceutical R&D and President of its Vaccines Division. Former US President Donald Trump appointed him to lead his administration’s efforts to produce and distribute Covid-19 vaccines last year. He stepped down from his post in January before President Joe Biden’s new administration took office.